Quantcast

Latest Sirolimus Stories

2009-09-30 07:00:00

UNION CITY, Calif., Sept. 30 /PRNewswire/ -- MacuSight, a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions, today provided a clinical development update for Perceiva, the company's proprietary ocular sirolimus product. The company has completed patient enrollment in four ongoing Phase 2 clinical trials of Perceiva and plans to announce data from these studies in the first half of 2010. All four studies are being conducted at...

2009-09-23 14:16:00

SAN FRANCISCO, Sept. 23 /PRNewswire/ -- OrbusNeich announced today that pre-clinical data involving porcine coronary models demonstrate that the company's Combo Bio-engineered Sirolimus Eluting Stent (Combo Stent) may offer advantages to the Cypher(R) sirolimus eluting stent and the XIENCE(TM) V everolimus eluting stent. Specifically, histological and optical coherence tomography (OCT) data out to 28 days show that the Combo Stent had lower neointimal hyperplasia and stenosis, as well as...

2009-09-21 14:53:38

A new type of sirolimus-eluting stent (SES) successfully showed significantly greater neointimal suppression than the paclitaxel-eluting stent (PES) with greater vessel wall integrity surrounding the stent, confirming the finding of superiority of the SES over the PES stent for the trial's primary endpoint of in-stent late loss. Results from the RES-ELUTION I Trial on the safety and effectiveness of a new sirolimus-eluting stent in the treatment of coronary artery disease (a single...

2009-09-21 14:30:31

Results of a multicenter study in Asia, demonstrating that drug-eluting stents are effective with a low rate of complications in diabetic patients, will be presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF). The study, "The Effect of Drug-Eluting Stents on Clinical and Angiographic Outcomes in Diabetic Patients: Multicenter Registry in Asia," compared the safety and efficacy of sirolimus...

2009-07-14 12:00:57

The U.S. Food and Drug Administration is ordering manufacturers of some immunosuppressant drugs used in kidney transplants to change their labeling. The FDA said the updated labels must reflect an increased risk of infections. The required label changes affect drugs used to help prevent rejection of transplanted organs. The drugs are Rapamune (sirolimus), Sandimmune (cyclosporine), and three generic drugs, Neoral (cyclosporine modified), Cellcept (mycophenolate mofetil) and Myfortic...

4f646b6b7bc94ced7193575316c474711
2009-07-08 15:30:00

A compound in the soil of Easter Island in the South Pacific significantly extends the lifespan of older mice, researchers at the University of Texas reported on Wednesday. The molecule, known as "rapamycin" after the island's Polynesian name, Rapa Nui, is a bacterial byproduct discovered in a sample obtained from the remote Pacific archipelago during the 1970s. The researchers gave the rapamycin to mice that were the human equivalent of 60 years old, and found it expanded lifespans by 28 to...

2009-07-08 14:00:25

Transplant patients rely on drugs to prevent graft rejection, but at the cost of serious side effects. The class of immunosuppressive drugs known as calcineurin inhibitors (examples are cyclosporine and tacrolimus) can damage patients' kidneys and lead to high blood pressure, among other problems.A combination of treatments can effectively replace calcineurin inhibitors in preventing graft rejection when kidney transplants are performed on monkeys, scientists at the Emory Transplant Center...

f9e31f191c2d600df341a5622c4df9ef1
2009-06-26 14:20:00

New research suggests that a common immunosuppressive drug may have the ability to boost the power of vaccines, BBC News reported. The drug rapamycin is commonly given to transplant patients to stop their bodies rejecting donor organs, but scientists at Emory University discovered during tests on mice and monkeys that it enhanced the response of their immune system to experimental vaccines. The study also raises hopes of a new generation of potent vaccines. According to the research published...

2009-06-22 10:06:34

Rapamycin, a drug given to transplant recipients to suppress their immune systems, has a paradoxical effect on cells responsible for immune memory, scientists at the Emory Vaccine Center have discovered.In experiments conducted in both mice and monkeys, rapamycin can stimulate the formation of memory CD8 T cells, which enable the immune system to respond faster and stronger to an infectious agent upon a second encounter.The results were published online ahead of print June 21 in Nature. The...

9a667d701bf8f1571949e44f18fca8a31
2009-06-15 16:30:00

Tumor metabolism discovery opens new detection and treatment possibilities for rare form of colon cancerPeople who suffer from Peutz-Jeghers syndrome, a rare inherited cancer syndrome, develop gastrointestinal polyps and are predisposed to colon cancer and other tumor types. Carefully tracing the cellular chain-of-command that links nutrient intake to cell growth (and which is interrupted in Peutz-Jeghers syndrome), allowed researchers at the Salk Institute for Biological Studies to exploit...


Word of the Day
humgruffin
  • A terrible or repulsive person.
Regarding the etymology of 'humgruffin,' the OED says (rather unhelpfully) that it's a 'made-up word.' We might guess that 'hum' comes from 'humbug' or possibly 'hum' meaning 'a disagreeable smell,' while 'gruffin' could be a combination of 'gruff' and 'griffin.'